Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | CA7 | P43166 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | STS | P08842 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87450 | 0.85 | CA1 (0.83) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL6896360 | 0.84 | LMNA (0.71) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL27667926 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL29504635 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL27647500 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL7746905 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL30271267 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL27667923 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL21440358 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL27647572 | 0.83 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| CN-101006082-B | Histamine H3 receptor agents, methods of preparation and therapeutic uses | LILLY CO ELI | 2010-09-29 | — | — | CN | disclosed |
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007103456-A2 | PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES | TRIMERIS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103456-A2 | PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES | TRIMERIS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| CN-101006082-A | Histamine H3 receptor agents, methods of preparation and therapeutic uses | LILLY CO ELI (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1784400-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006023462-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
| US-5607944-A | ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | LMNA 4237/4885CYP1A2 2615/4885CYP3A4 3045/4885 |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | LMNA 4170/4885CYP1A2 2461/4885CYP3A4 2976/4885 |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | LMNA 2555/4885CYP1A2 8/4885CYP3A4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.